Why Is NEUROCRINE BIOSCIENC (NBIX) Stock Down Today?

Neurocrine Biosciences (NBIX) fell 9.67% to $167.57 in early trading on July 30, 2026, marking a sharp reversal from a strong earnings report and raised sales guidance. The stock opened with a 1.5% gap up but quickly reversed to a session low of $167.46 within an hour of the market open. The move reflects a volatile intraday reaction to the firm's recent performance and mixed investor sentiment.

What Happened

Neurocrine reported second-quarter 2026 results that exceeded expectations, including non-GAAP EPS of $2.85, which beat by $0.89, and revenue of $959 million, up 39% year-over-year. The company raised its 2026 INGREZZA net sales guidance to $2.825 billion to $2.875 billion and announced the successful integration of VYKAT XR. Analysts from Needham and Guggenheim raised their price targets for the stock, with Needham setting a $204 target and Guggenheim at $200. Despite these positive developments, the stock opened with a gap up and then fell sharply, suggesting a rapid reassessment by traders.

What The Data Shows

The intraday session showed a dramatic reversal, with the stock opening at $188.30 and hitting a high of $189.53 before plunging to a low of $167.46. Volume was 0.5 million shares, which is 0.4 times the 3-month average. Recent insider transactions show 15 sales totaling $62.4 million in the last 90 days, with the most recent sale reported on July 30. The stock is currently trading within its 52-week range of $122.14 to $186.12, below its 52-week high but above its 52-week low.

What To Watch

Neurocrine has no upcoming earnings date in the near term, but investors will continue to monitor analyst coverage and insider activity for further clues on market sentiment. The stock’s volatility and mixed signals from insiders suggest ongoing evaluation by market participants.